Should Paxil Be Stopped Before Starting Auvelity?
Yes, paroxetine (Paxil) should be discontinued before initiating Auvelity, with a gradual taper over 1-2 weeks to minimize discontinuation syndrome, followed by a washout period before starting Auvelity to reduce the risk of serotonin syndrome and drug-drug interactions.
Critical Safety Concerns
Serotonin Syndrome Risk
Auvelity contains dextromethorphan, which is a serotonergic agent. Concomitant use of Auvelity with SSRIs like paroxetine may cause serotonin syndrome, a potentially life-threatening condition characterized by altered mental status, hypertension, restlessness, myoclonus, hyperthermia, hyperreflexia, diaphoresis, shivering, and tremor 1. The FDA label explicitly warns about this risk when combining Auvelity with SSRIs 1.
Guidelines emphasize that caution should be exercised when combining two or more non-MAOI serotonergic drugs, including SSRIs and dextromethorphan-containing medications 2. Symptoms can arise within 24-48 hours after combining medications and can progress to fever, seizures, arrhythmias, and unconsciousness, which can be fatal 2.
Significant Pharmacokinetic Interaction
A critical drug-drug interaction exists between paroxetine and dextromethorphan/bupropion. Research demonstrates that when paroxetine is added to dextromethorphan/quinidine (a similar formulation), plasma exposure of dextromethorphan increases by 50% and quinidine by 40% 3. Conversely, adding dextromethorphan/quinidine to paroxetine increases paroxetine exposure by 30% 3.
Both paroxetine and bupropion (a component of Auvelity) are CYP2D6 inhibitors, and paroxetine is also a CYP2D6 substrate 2. This creates a compounding inhibition effect that significantly elevates drug levels, increasing the risk of dose-related adverse effects including neuropsychiatric reactions 1.
Discontinuation Strategy
Tapering Paroxetine
Paroxetine has been specifically associated with discontinuation syndrome characterized by dizziness, fatigue, lethargy, general malaise, myalgias, chills, headaches, nausea, vomiting, diarrhea, insomnia, imbalance, vertigo, sensory disturbances, paresthesias, anxiety, irritability, and agitation 2. This occurs more prominently with paroxetine than other SSRIs due to its shorter half-life and lack of active metabolites 4.
Gradual tapering over 1-2 weeks is essential to minimize these withdrawal symptoms. Research shows that abrupt discontinuation of paroxetine at doses above 20 mg/day causes marked sleep disturbances and dizziness, with rapid remission when the drug is reintroduced 4.
Washout Period
After completing the paroxetine taper, allow a washout period of at least 5-7 days before initiating Auvelity. This allows paroxetine levels to decline sufficiently (paroxetine has a half-life of approximately 21 hours) and reduces the risk of serotonergic overlap.
Initiating Auvelity
Once paroxetine has been discontinued and the washout period completed:
- Start Auvelity at one tablet once daily in the morning for 3 days, then increase to the maximum recommended dosage of one tablet twice daily, separated by at least 8 hours 1
- Monitor closely for serotonin syndrome symptoms during the first 24-48 hours after each dose change 2
- Assess blood pressure before and during treatment, as Auvelity can increase blood pressure 1
- Screen for any residual paroxetine effects including sexual dysfunction, which is notably higher with paroxetine than other SSRIs 5
Clinical Pitfalls to Avoid
- Never overlap paroxetine and Auvelity - The combined serotonergic effect and CYP2D6 inhibition create unacceptable safety risks
- Do not abruptly stop paroxetine - This causes severe discontinuation syndrome, particularly at doses >20 mg/day 4
- Do not rush the transition - Allow adequate time for paroxetine clearance before starting Auvelity
- Monitor for treatment-resistant depression during the transition - Have a contingency plan if symptoms worsen during the medication switch
Special Considerations
A case report documents a patient with treatment-resistant depression who overdosed on Auvelity and was subsequently successfully managed on paroxetine 40 mg daily 6. This underscores that these medications should not be combined and that careful monitoring is essential during transitions, particularly in patients with suicidal ideation.
The evidence strongly supports discontinuing paroxetine before starting Auvelity to prevent potentially fatal serotonin syndrome and avoid significant drug-drug interactions that increase adverse event risk.